Your browser doesn't support javascript.
loading
Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559).
Hotchkiss, Richard S; Colston, Elizabeth; Yende, Sachin; Angus, Derek C; Moldawer, Lyle L; Crouser, Elliott D; Martin, Greg S; Coopersmith, Craig M; Brakenridge, Scott; Mayr, Florian B; Park, Pauline K; Ye, June; Catlett, Ian M; Girgis, Ihab G; Grasela, Dennis M.
Afiliação
  • Hotchkiss RS; Department of Anesthesiology, Washington University School of Medicine, St Louis, MO.
  • Colston E; Department of Anesthesiology, Innovative Medicines Development, Bristol-Myers Squibb, Princeton, NJ.
  • Yende S; Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA.
  • Angus DC; The CRISMA Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
  • Moldawer LL; The CRISMA Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
  • Crouser ED; Department of Surgery, University of Florida College of Medicine, Gainesville, FL.
  • Martin GS; Department of Medicine, The Ohio State University, Columbus, OH.
  • Coopersmith CM; Department of Medicine, Division of Pulmonary, Allergy, Critical Care & Sleep Medicine, Emory University, Atlanta, GA.
  • Brakenridge S; Department of Surgery and Emory Critical Care Center, Emory University, Atlanta, GA.
  • Mayr FB; Department of Surgery, University of Florida College of Medicine, Gainesville, FL.
  • Park PK; Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA.
  • Ye J; The CRISMA Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
  • Catlett IM; Department of Surgery, University of Michigan, Ann Arbor, MI.
  • Girgis IG; Department of Anesthesiology, Innovative Medicines Development, Bristol-Myers Squibb, Princeton, NJ.
  • Grasela DM; Department of Anesthesiology, Innovative Medicines Development, Bristol-Myers Squibb, Princeton, NJ.
Crit Care Med ; 47(5): 632-642, 2019 05.
Article em En | MEDLINE | ID: mdl-30747773
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sepse / Anticorpos Monoclonais Humanizados / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Crit Care Med Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Macau País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sepse / Anticorpos Monoclonais Humanizados / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Crit Care Med Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Macau País de publicação: Estados Unidos